On October 11, 2017, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a new CDR Update (Issue 129). Based on feedback from stakeholders, CADTH will be implementing the proposed revision to the resubmission eligibility criteria and a new randomized controlled trial will no longer be required ... Read More
News & Events
12
Oct2017
11
Oct2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of September 30, 2017:
51 negotiations are currently underway with 6 new files added since the last update of August 31, 2017:
Fibristal (ulipristal acetate): Used to treat uterine fibroids (2nd cycle pre-surgery)
Glatect ... Read More
29
Sep2017
The Hearing Panel of the Patented Medicine Prices Review Board has made public its decision in the matter of Alexion Pharmaceuticals Inc. and the medicine Soliris. The Panel orders Alexion to:
pay to Her Majesty in right of Canada an amount calculated by the parties in accordance with Schedule ... Read More
29
Sep2017
INESSS Releases Additional Information on the Continuous Evaluation of Drug Products
/ INESSS, What's New
On September 29, 2017, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) released a notice to manufacturers announcing the details on the process for the admissibility of submission applications for registration. A manufacturer can submit an application for registration to INESSS only when all required documents are ... Read More
29
Sep2017
On September 28, 2017, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a new CDR Update (Issue 128) describing the following changes.
Revised Procedure for Advance Notification of Pending CDR Submissions and Resubmissions
CADTH has received numerous inquiries regarding challenges interpreting and complying with the ... Read More
12
Sep2017
Canada’s “health leaders” sponsoring the Open Pharma campaign should have checked with the Patented Medicine Prices Review Board (PMPRB) before advocating their ill-conceived and impractical proposal to have the federal government amend the Patented Medicines Regulations to force drug manufacturers to disclose payments to physicians via the PMPRB.
An ... Read More
12
Sep2017
On September 11, 2017, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a new CDR Update (Issue 127) describing the following changes.
Extended Initiation Range for January 2018 CDEC Meeting
CADTH has extended the initiation range for its Common Drug Review (CDR) submissions targeting the January 17, ... Read More
11
Sep2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of August 31, 2017:
47 negotiations are currently underway with 6 new files added since the last update of July 31, 2017:
Brilinta (ticagrelor): Used with ASA to prevent atherothrombotic events with history ... Read More
08
Sep2017
Notice to Manufacturers – Medications Under Review for February 2018 List Update
/ INESSS, Quebec, What's New
On September 7, 2017, the Institut national d’excellence en santé et en services sociaux (INESSS) released the list of medications for which a registration application was submitted for the February 2018 list update as well as the medications pending a Health Canada Notice of Compliance to be reviewed.
Health professionals, citizens, ... Read More
23
Aug2017
NOW LIVE: PDCI’s Information Sharing Webpage: Responses to Health Canada’s Patented Medicines Regulations Consultation
/ Canada, PMPRB, What's New
PDCI has now published its information sharing webpage which aggregates submissions made by individuals and organizations in response to Health Canada’s Consultation on Proposed Amendments to the Patented Medicines Regulations.
Click Here to Visit PDCI’s Information Sharing Webpage.
The submissions have been provided by individuals & organizations on a completely voluntary ... Read More